Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Coming into Focus

By Drug Discovery Trends Editor | December 3, 2008

What if the experimental subject in a longitudinal study could serve as its own control? Behold: the novel advantages of in vivo toxicology imaging.

undefined

click to enlarge
NanoSPECT/CT images: The biodistribution of radiotherapeutic peptide in a mouse. (Source: Prof. T. Behr Univ. of Marburg, Germany)

The gross assumption of a controlled study of living subjects is that the controls are, for endpoint purposes, identical to the active treatment cohort. Unfortunately, it just ain’t so. Therefore, the ideal would be to do experiments where you could observe both the treated and untreated state within the same organism, and this is now increasingly possible with in vivo imaging.

‘We can use the same animal each time,’ says Kenneth Dunn, PhD, vice president of scientific development, INphoton, Indianapolis, Ind. ‘It serves as its own internal control. We typically open up the animal for imaging, then close it and return it to its cage. For rats, that’s not a big deal.’

Once open, Dunn is able to image his animals with fluorescence microscopy, a technique now coming into its own in preclinical toxicology. ‘Pharma executives know about PET and SPECT imaging, but it’s taken a while for them to appreciate the value of cellular and subcellular imaging that we can offer,’ he explains.

Indeed, INphoton, itself, has only recently come into being, after its founders at Indiana University developed their techniques of small animal, intravital imaging as part of a National Institutes of Health (NIH) grant. Once word of the technique spread, Dunn and colleagues were prompted to form INphoton to provide answers for a growing number of outside queries. ‘One company came to us with a drug that had great efficacy,’ Dunn relates, ‘but there was evidence that the drug wasn’t being cleared from the cell.’ The issue could not be tackled histologically because the drug can’t be fixed in tissue—a reality of many compounds. The only way it could be evaluated was with microscopy. ‘We added a fluorophore and watched it get internalized. And then, in 24 hours, it was cleared.’ The ultimate result? ‘The FDA was satisfied by our finding,’ he says.

The resolution of the technique can be astounding, and has obvious implications for preclinical toxicology. ‘We can correlate drug distribution with functional readouts,’ says Dunn—apoptosis, necrosis, mitochondrial injury—all the standard toxicological touch points. ‘The difference with this technique is a matter of figuring out how a car accident happened—we can go in and query which cells are dying, while they are dying, and get the precise chronology of the injury process.’
 
Picture perfect
Fluorescence microscopy does have its limitations. For instance, a fluorophore’s size may affect the pharmacokinetics of the agent to which it is linked, and the overall technique is not necessarily scalable; this not as true for SPECT (single photon emission computed tomography) or NanoSPECT, an innovation from the company Bioscan. ‘This is the first in a new generation of SPECT instruments for small animals,’ says Staf Van Cauter, executive vice president, Bioscan, Washington, D.C. ‘This has a resolution and volumes that are sub-microliter so that when you take a preclinical image of a mouse, you’re actually dealing with reconstruction volumes that are essentially the same as, or better than, what you’re dealing with in clinical images.’ That means it’s translatable—you can take the same imaging protocols into humans as the development of your drug moves forward.

NanoSPECT tracers do not have the same size limitations as fluorophores, and there is very little absorption of the emission by the body that’s being examined. ‘The targeting is very precise and finds its way out with very little scattering (and without surgery).’ However, in this case the image is of a higher magnitude, that being from whole organs rather than from specific cell types as described above.

undefined

click to enlarge
The 4D scan (3D tomagraphic images with time as the 4th dimension) of renal toxicity. (Source: Prof. M. De Jong, ErasmusMC, Rotterdam, The Netherlands)

A typical use for NanoSPECT in toxicology is to look at biodistribution and washout times, as well as longitudinal studies of tissue morphology. One such experiment facilitated by Bioscan was to look for kidney damage suspected to be caused by a radiotherapeutic. ‘We could look at it over time and see structural changes,’ says Van Cauter, adding that there are many tests of human organ function already available in nuclear medicine, which can carry over into animals.

Picture of health
Techniques have been recently developed to look at toxicological effects in another organ: the heart. Kathy Gabrielson, PhD, Johns Hopkins Medical Institutions, Baltimore, Md., uses ultrasound. ‘Ultrasound can tell you if the heart is enlarged. It can’t tell you if the cardiomyocytes are enlarged, but it can tell you if the wall itself is enlarged, or if the heart is contracting normally.’ As with the other in vivo techniques, animals can be imaged repeatedly, enabling long-term studies of atherosclerosis, or other signs of cardiovascular impairment.

Gabrielson was initially interested in the technique when a controversy arose regarding the use of doxorubicin with the breast cancer drug, Herceptin. Signals had emerged from the clinic that the combination, though highly effective, was cardiotoxic. Mice were administered the drugs, then 2D images were obtained of gross morphology. ‘Once we have that image, we can shift to another (higher resolution) modality called ‘M-mode’, which allows the capture of contractile motion over time,’ Gabrielson explains. These data can literally illustrate the presence and magnitude of compromised ejection fractions—a prime indicator of heart health.

Results from these investigations helped form the hypothesis explaining the adverse doxorubicin/Herceptin interaction. Though other markers of cardiotoxicity, as detected by ultrasound, are being considered, Gabrielson is currently using the technique to look at animal models of cardiovascular disease, and the effect of related therapeutic agents. She is, however, very enthusiastic about the use of imaging in preclinical toxicology and urges anyone with an interest to seek out one of the shared facilities created by the National Cancer Institute’s Small Animal Imaging Resource Project.

What’s Wrong with this Picture?

‘In preclinical animal studies, imaging has taken off in the last five to 10 years,’ says Patrick McConville, PhD, director of imaging, MIR Preclinical Services (a Charles River Company), Ann Arbor, Mich. ‘It’s very much happened in parallel with the advent of targeted therapies.’ However, from McConville’s perspective within a CRO, he sees the use of imaging in toxicology as something that will remain a largely untapped resource—at least for the short term.

‘All tox work from an industry/FDA perspective has to happen under GLP conditions, and it’s not easy to get imaging done under that sort of scenario. To my knowledge, currently there are no imaging centers that are also GLP-compliant.’ For McConville, a 10-year veteran of imaging research, the only way imaging can play a major role in toxicology is for the FDA to change the way it looks are certain kinds of data—and that has to be driven by validation. ‘The FDA has to somehow be satisfied that certain types of imaging provide information that either there’s no other way to get at, or improved in such a way that imaging is then required.’

McConville is confident that the change is coming. (He’s just not willing to put his money on when.) He sees the first regulatory approval to be granted for biodistribution studies, and predicts that approved techniques will get more elegant from there. ‘There are imagible biomarkers already available that will tell you about the event that’s causing the toxic effect, not merely knowing where the drug is. That’s vitally important,’ he says.

In the meantime, anyone who wishes to get an idea of what the GLP regulations for toxicology imaging might look like should peruse the recently issued position paper from the Society of Toxicologic Pathology regarding GLP compliance with ex vivo digital histological images: Code of Federal Regulations, volume 21, parts 11 and 58 (Toxicol Pathol. 2007;35(3):450-5). But fair warning—it’s not a pretty picture.

 

 

About the Author
Neil Canavan is a freelance journalist of science and medicine based in New York.

This article was published in Drug Discovery & Development magazine: Vol. 11, No. 12, December, 2008, pp. 22-24.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE